<DOC>
	<DOCNO>NCT01608269</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , antivira activity Epzicom virologically control HIV subject .</brief_summary>
	<brief_title>Nucleoside Switch Pilot Virologically Controlled HIV Subjects With Decreasing CD4 Cells Who Have Received TDF-based ARV Therapy</brief_title>
	<detailed_description>Utilizing ABC/3TC FDC tablet NRTI backbone , open label study compare safety efficacy ABC/3TC use replacement subject suboptimal CD4- cell count receive TDF/FTC . TYhis study conduct 48 week HIV infect , HLA*B5701 begative subject initially suppress HAART regiment include TDF/FTC QD .</detailed_description>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>HIV1 RNA ≤ 50 copies/mL HIV1 Ultrasensitive RNA , Quantitative . Treatment experienced subject virologically stable HAART regimen contain tenofoviremtricitabine tenofovirlamivudine . Subject CD4 cell increase 15 % and/or decrease 15 % previous 12 month period . ≥ 18 year age Cognitive ability understand provide write informed consent willingness participate comply study protocol Less 7 day prior ART license investigational compound Patient currently treat active opportunistic infection ( OI ) consistent CDC definition ( Appendix C ) within 30 day screen Vital sign , physical examination laboratory result exhibit evidence acute illness A female eligible enter participate study : Nonchildbearing potential ( i.e. , physiologically incapable become pregnant , include female postmenopausal ) Childbearing potential , negative serum pregnancy test screen , agree one following : Complete abstinence intercourse 2 week prior administration study drug , throughout study , least 2 week completion premature discontinuation study account elimination investigational drug . Should patient decide become sexually active course study , must counsel willing use one birth control method list : Double barrier method ( male condom/spermicide , male condom/diaphragm , diaphragm/spermicide ) Any intrauterine device ( IUD ) publish data show expected failure rate &lt; 1 % per year ( IUDs meet criterion ) Sterilization ( female patient male partner female patient ) Any method publish data show low expected failure rate method &lt; 1 % per year . Patient active AIDSdefining opportunistic infection disease accord 1993 CDC AIDS surveillance definition ( Clinical Category C ) 30 day prior baseline , opinion investigator , would preclude patient participate study ( See Appendix C ) . Patient HLA B5701 Positive Patient determine ≥2 thymidine analog mutation RT History active substance abuse , exclude cannabis , psychiatric illness , opinion investigator , would preclude compliance protocol , dose schedule assessment . Patient either pregnant time screen evaluation breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>